Revealing what makes bacteria life-threatening
Queensland researchers have discovered that a mutation allows some E. coli bacteria to cause severe disease in people while other bacteria are harmless, a finding that could help to combat antibiotic resistance.
Professor Mark Schembri and Dr Nhu Nguyen from IMB and Associate Professor Sumaira Hasnain from Mater Research found the mutation in the cellulose making machinery of E. coli bacteria. The research was published in Nature Communications.
Professor Schembri said the mutation gives the affected E. coli bacteria the green light to spread further into the body and infect more organs, such as the liver, spleen and brain.
"Bad' bacteria can't make cellulose
“Our discovery explains why some E. coli bacteria can cause life-threatening sepsis, neonatal meningitis and urinary tract infections (UTIs), while other E. coli bacteria can live in our bodies without causing harm,” Professor Schembri said.
“The ‘good’ bacteria make cellulose and ‘bad’ bacteria can’t.”
Bacteria produce many substances on their cell surfaces that can stimulate or dampen the immune system of the host.

Inflammation and spreading through the body
“The mutations we identified stopped the E. coli making the cell-surface carbohydrate cellulose and this led to increased inflammation in the intestinal tract of the host,” Professor Schembri said.
“The result was a breakdown of the intestinal barrier, so the bacteria could spread through the body.”
In models that replicate human disease, the team showed that the inability to produce cellulose made the bacteria more virulent, so it caused more severe disease, including infection of the brain in meningitis and the bladder in UTIs.
Finding new ways to prevent infection

Associate Professor Hasnain said understanding how bacteria spread from intestinal reservoirs to the rest of the body was important in preventing infections.
“Our finding helps explain why certain types of E. coli become more dangerous and provides an explanation for the emergence of different types of highly virulent and invasive bacteria,” she said.
Professor Schembri said E. coli was the most dominant pathogen associated with bacterial antibiotic resistance.
“In 2019 alone, almost 5 million deaths worldwide were associated with bacterial antibiotic resistance, with E. coli causing more than 800,000 of these deaths,” he said.
“As the threat of superbugs that are resistant to all available antibiotics increases worldwide, finding new ways to prevent this infection pathway is critical to reduce the number of human infections.”
This article was republished from the University of Queensland website. Read the original here.
Enjoy reading ASBMB Today?
Become a member to receive the print edition four times a year and the digital edition monthly.
Learn moreGet the latest from ASBMB Today
Enter your email address, and we’ll send you a weekly email with recent articles, interviews and more.
Latest in Science
Science highlights or most popular articles

What’s in a diagnosis?
When Jessica Foglio’s son Ben was first diagnosed with cerebral palsy, the label didn’t feel right. Whole exome sequencing revealed a rare disorder called Salla disease. Now Jessica is building community and driving research for answers.

Peer through a window to the future of science
Aaron Hoskins of the University of Wisconsin–Madison and Sandra Gabelli of Merck, co-chairs of the 2026 ASBMB annual meeting, to be held March 7–10, explain how this gathering will inspire new ideas and drive progress in molecular life sciences.

Glow-based assay sheds light on disease-causing mutations
University of Michigan researchers create a way to screen protein structure changes caused by mutations that may lead to new rare disease therapeutics.

How signals shape DNA via gene regulation
A new chromatin isolation technique reveals how signaling pathways reshape DNA-bound proteins, offering insight into potential targets for precision therapies. Read more about this recent MCP paper.

A game changer in cancer kinase target profiling
A new phosphonate-tagging method improves kinase inhibitor profiling, revealing off-target effects and paving the way for safer, more precise cancer therapies tailored to individual patients. Read more about this recent MCP paper.

How scientists identified a new neuromuscular disease
NIH researchers discover Morimoto–Ryu–Malicdan syndrome, after finding shared symptoms and RFC4 gene variants in nine patients, offering hope for faster diagnosis and future treatments.